Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 0.90 |
| ▸ | FNTB | P49356 | 14/20 | 0.90 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.90 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.77 |
| ▸ | HRAS | P01112 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29395402 | 1.00 | FNTA (0.90) | FNTAFNTBTDP1PGGT1BHRAS | |
| Trifluoroacetic Acid SCHEMBL5078478 | 1.00 | FNTA (0.90) | FNTAFNTBTDP1PGGT1BHRAS | |
| SCHEMBL29381983 | 0.95 | FNTA (1.00) | FNTAFNTBTDP1PGGT1BHRAS | |
| SCHEMBL8365606 | 0.95 | FNTA (1.00) | FNTAFNTBTDP1PGGT1BHRAS | |
| SCHEMBL6056511 | 0.95 | FNTA (1.00) | FNTAFNTBTDP1PGGT1BHRAS | |
| SCHEMBL8586036 | 0.95 | FNTA (1.00) | FNTAFNTBTDP1PGGT1BHRAS | |
| Hydrochloric Acid SCHEMBL8492805 | 0.94 | FNTA (0.98) | FNTAFNTBTDP1PGGT1BHRAS | |
| Hydrochloric Acid SCHEMBL29686212 | 0.94 | FNTA (0.98) | FNTAFNTBTDP1PGGT1BHRAS | |
| Hydrochloric Acid SCHEMBL8492799 | 0.94 | FNTA (0.98) | FNTAFNTBTDP1PGGT1BHRAS | |
| Trifluoroacetic Acid SCHEMBL5084894 | 0.93 | FNTA (0.90) | FNTAFNTBTDP1PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024194402-A1 | FARNESYL TRANSFERASE INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | claimed |
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024194402-A1 | FARNESYL TRANSFERASE INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | disclosed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| CN-106667988-A | Application of farnesyltransferase inhibitors in preparation of medicine for facilitated cholinergic nerve system | 南京医科大学 | 2017-05-17 | — | — | CN | disclosed |
| US-20080139457-A1 | Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | FNTA 874/4885FNTB 1328/4885TDP1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.